Key Points for Decision Makers {#FPar01}
==============================

Considering the worldwide increase in the prevalence of conditions such as obesity and hypertension, patients with type 1 diabetes (T1D) often present with concomitant cardiovascular disease (CVD) and cardiovascular risk factors (CVRF), which can significantly increase the economic burden of disease.This analysis of a large health insurance claims database in the US revealed increased healthcare resource utilization and costs among adult patients with T1D and CVD, and/or CVRF compared with those with neither.Management of cardiovascular comorbidities constitutes an important component of care for adults with T1D; optimal management is critical to improve patient outcomes and reduce healthcare costs.

Introduction {#Sec1}
============

Very poor glycemic control has been associated with a tenfold-increased risk of death from cardiovascular disease (CVD) in type 1 diabetes (T1D) compared with the general population \[[@CR1]\]. Patients with T1D also show an approximately twofold greater incidence of hospitalization due to heart failure than people without diabetes; advanced age and diabetes duration, presence of obesity and renel impairment, as well as history of smoking and prior ischemic heart disease and stroke are good predictors of increased risk for this heart condition \[[@CR2]\].

Various risk factors with a significant negative impact on the prevalence of CVD among patients with T1D have been identified throughout the years, namely hypertension, proteinuria, obesity, dysglycemia, dyslipidemia, tobacco use, advanced age, and longer duration \[[@CR3]\]. Recent medical advances resulting in decreased mortality from renal impairment and acute metabolic complications have also contributed to an increase in the number of patients with T1D who are exposed to age-related cardiovascular risk factors (CVRF) and CVD \[[@CR4]\].

The epidemiological and disease burden estimates of CVRF and CVD in T1D have commonly been extrapolated from studies conducted in type 2 diabetes (T2D) or general diabetes populations \[[@CR3]\], but there are differences in the age of onset, duration, and natural history of CVD between patients with T1D and T2D, as well as variations in the pathogenesis of cardiovascular conditions such as atherosclerosis \[[@CR4], [@CR5]\].

The incidence of coronary heart disease for men and women with T1D aged 20--40 years was determined to be approximately 5 and 11 times, respectively, the rates for individuals without diabetes \[[@CR6]\]. The excess risk of mortality and CVD increases with decreasing age of onset of T1D, and is higher for women \[[@CR5]\]. In fact, the estimated life expectancy at 20 years of age is reduced by 11 years for men and almost 13 years for women with T1D compared with the general population, and approximately one-third of the excess risk of death is due to CVD \[[@CR7]\]. However, most of these large recent studies of CVD in patients with T1D have used data collected from European registries \[[@CR1], [@CR5]--[@CR9]\]. In the US, the Pittsburgh Epidemiology of Diabetes Complications study revealed that CVD was responsible for 40% of the deaths among patients with T1D for \> 20 years \[[@CR10]\], but there is a paucity of data on the impact of the cardiovascular burden on diabetes-related and all-cause health economic outcomes in the US.

It is particularly important for population health managers to have comprehensive and up-to-date data that elucidate the cardiovascular burden among patients with T1D. To meet this current gap in knowledge, the present analysis evaluated health insurance claims from a large database---the Optum^®^ Clinformatics™ Data Mart database, which comprises approximately 17 million annual covered lives---to evaluate the real-world prevalence of and disease burden (as measured by health economic outcomes) associated with CVRF and CVD in T1D in the US.

Methods {#Sec2}
=======

Design and Eligibility Criteria {#Sec3}
-------------------------------

In a retrospective analysis of healthcare insurance claims, data from the Optum^®^ Clinformatics™ Data Mart database were collected from January 1, 2015, to December 31, 2017, and analyzed. Optum^®^ Clinformatics™ Data Mart is a database of administrative health claims for members of a large managed care company affiliated with OptumInsight \[[@CR11]\]. It includes approximately 17 million annual covered lives, based on enrollment in a UnitedHealth insurance plan as of June 2018, for a total of approximately 60 million covered lives over an 11-year period. It comprises commercial health plan data, but also includes historic claims for managed Medicaid and Medicare Plus Choice members; the population covered is geographically diverse, spanning all 50 states in the US. In addition to medical claims, pharmacy claims, and laboratory results, the database includes information on inpatient stays, standard pricing, and member eligibility data. All data are de-identified prior to acquisition \[[@CR11]\].

This analysis included patients with at least one T1D medical claim during the identification period from January 1, 2016, to December 31, 2016; the date of first medical claim with a diagnosis code for T1D in the identification period was defined as the index date. The diagnosis of diabetes was classified as T1D, according to a validated algorithm developed by Klompas et al. \[[@CR12]\] using the combination of diabetes diagnosis codes and antihyperglycemic treatment pattern in T1D. The positive predictive value for the Klompas algorithm was 88% in the original publication \[[@CR12]\] and 94.5% in an external validation study \[[@CR13]\].

Patients had to be ≥ 18 years at the index date and have continuous eligibility (without gaps) for 12 months prior to the index date and until the earliest occurrence of death (based on data from the Social Security Administration) or the end of the 12-month period after the index date or December 31, 2017, while maintaining continuous enrollment. Patients were excluded if they met any of the following criteria: (1) patients with follow-up \< 30 days post-index; (2) women who were pregnant at any time during the 12-month baseline period; and (3) no prescription claim for rapid-acting or short-acting insulin within 6 months prior to the index date.

Patients were divided into three cohorts based on baseline presence of CVD and/or CVRF \[details on International Classification of Diseases (ICD) \[[@CR14]\] codes are provided in the Electronic supplementary material, ESM\]. The CVD cohort included patients with CVD, defined as ≥ 1 medical claim for myocardial infarction, stroke (ischemic or hemorrhagic), coronary heart disease, heart failure, cardiac arrhythmia (including atrial fibrillation or flutter), pulmonary embolism, or peripheral vascular disease; patients in this cohort could also have CVRF in the presence of CVD. The CVRF cohort included patients with CVRF, defined as ≥ 1 medical claim of hypertension and ≥ 1 prescription for an antihypertensive agent, or ≥ 1 medical claim for hypercholesterolemia or hyperlipidemia and ≥ 1 prescription for a lipid-modifying medication, or ≥ 1 medical claim for chronic kidney disease (CKD), or ≥ 1 medical claim for obesity, but without CVD (details on diagnosis codes and National Drug Codes are provided in the ESM). Finally, the no-CVD/CVRF cohort included patients with no medical claims for CVD or CVRF, as defined above. This classification was strictly based on information captured during the baseline period.

Patients were followed for a maximum of 12 months after the index date. The analyses were carried out using the Python and R programming languages on Apache Spark and in accordance with a prespecified protocol, following the principles, regulations, and guidelines governing medical practice and ethics in the US for noninterventional studies and/or observational studies. No Institutional Review Board approval was required.

Outcome Variables {#Sec4}
-----------------

Patient baseline demographic data, including age, gender, health plan type, and geographic region, were collected at the index date. The period for assessing the prevalence of CVRF and CVD was from 12 months prior to the index date until the end of the follow-up period.

All-cause and diabetes-related healthcare resource utilization data were collected during the follow-up period. Healthcare resource utilization data included prescription medications, emergency department (ED) visits, inpatient admissions, inpatient length of stay (days), and outpatient physician office visits. Because not all patients were expected to have 12 months of follow-up, annualized all-cause and diabetes-related healthcare costs per patient were reported for inpatient admissions, ED visits, outpatient physician office visits, outpatient services, and prescription medications. Diabetes-related healthcare utilization and costs were defined as resource use and cost on medical claims with a primary or secondary diagnosis of diabetes and antihyperglycemic medications. All costs were inflation adjusted to 2018 US dollars using the annual medical care component of the Consumer Price Index \[[@CR15]\] to account for inflation from the time the cost was incurred to the end date of the analysis, which allowed for the direct comparison of costs during the analysis period.

Statistical Analyses {#Sec5}
--------------------

Descriptive statistical and univariate analyses were performed for prevalence and healthcare resource utilization and cost data. Differences between cohorts were assessed using chi-square tests for categorical variables and *t* tests for continuous variables; for the age variable, an overall *F* test was used to detect the presence of any differences among groups. Fisher's exact tests and/or nonparametric tests (e.g., the Wilcoxon rank-sum test for skewed data such as resource utilization/costs) were used as appropriate. Significant differences were determined by calculating *P* values and standardized mean differences (SMDs), defined as the absolute difference in sample means divided by an estimate of the pooled standard deviation of the variable. Significant differences between variables had to have *P* \< 0.05 and SMD \> 0.1.

The differences between groups with no CVD/CVRF and with CVRF or CVD were analyzed with a generalized linear model (GLM) that allowed for variation in both the link and the family of distribution and was based on the response variable for resource utilization---a GLM with a Poisson distribution and log link for count outcomes, a two-part model using logistic regression for the binomial component, and a standard overall least squares (OLS) model for cost outcomes. Multivariate analyses were adjusted for confounding variables that were found to be significantly different between patients among all cohorts in the univariate analysis, i.e., age, ethnicity, gender, health insurance plan type (commercial vs. Medicare), geographical region, modified Deyo--Charlson Comorbidity Index (DCI), and comorbidities (i.e., urinary tract infection, hypothyroidism, and depressive disorder). Poisson, quasi-Poisson, and negative binomial models were compared according to the Akaike information criterion and likelihood ratio test in order to select the most appropriate regression model \[[@CR16]\]. All statistical tests conducted were two-sided with a significance level of *α* = 0.05. Patients with T1D who met the study eligibility criteria were included in the final analysis.

Results {#Sec6}
=======

Baseline Demographic and Clinical Characteristics {#Sec7}
-------------------------------------------------

A total of 12,687 patients with T1D were included in the analysis (see Fig. [1](#Fig1){ref-type="fig"}): 2871 (23%) in the CVD cohort; 5371 (42%) in the CVRF cohort; and 4445 (35%) in the no-CVD/CVRF cohort. A total of 94 patients died during the 12-month follow-up period; all the other patients had a follow-up of 365 days.Fig. 1Patient attrition. *CVD* cardiovascular disease, *CVRF* cardiovascular risk factors, *ICD* International Classification of Diseases, *OAD*, oral antidiabetes drug, *T1D*, type 1 diabetes, *T2D*, type 2 diabetes. ^a^CVRF, including hypertension, hypercholesterolemia, hyperlipidemia, chronic kidney disease, and obesity. ^b^CVD, including myocardial infarction, stroke (ischemic or hemorrhagic), heart failure, cardiac arrhythmia, atrial fibrillation or flutter, coronary heart disease, pulmonary embolism, and peripheral vascular disease

The baseline demographic and clinical characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Patients in the no-CVD/CVRF cohort were significantly younger than those in the CVRF and CVD cohorts (mean ages of 35.8 vs. 53.0 and 62.1 years, respectively; *P* \< 0.001, SMD \> 0.1). The majority of the patients in all three cohorts were white (≥ 72%). Approximately one-third were located in the Midwest, and more than one-third were in the South.Table 1Demographic and clinical characteristics by diagnosis categoryNo-CVD/CVRF cohort (*n* = 4445)CVRF cohort (*n* = 5371)*P* value/SMD (CVRF vs. no-CVD/CVRF cohort)CVD cohort (*n* = 2871)*P* value/SMD (CVD vs. no-CVD/CVRF cohort)Age in years, mean (SD)35.8 (14.2)53.0 (14.4)\< 0.001/1.197\*62.1 (13.9)\< 0.001/1.871\*Women, *n* (%)2178 (49)2611 (49)0.617/0.0211369 (48)0.282/0.026Ethnicity, *n* (%)0.002/0.084\< 0.001/0.131\* African American236 (5)333 (6)236 (8) Asian81 (2)87 (2)37 (1) Hispanic246 (6)234 (4)132 (5) White3195 (72)3977 (74)2059 (72) Other/unknown687 (16)740 (14)407 (14)Geographic region, *n* (%)0.003/0.081\< 0.001/0.118\* Northeast434 (10)505 (9)328 (11) Midwest1354 (31)1622 (30)771 (27) South1614 (36)2131 (40)1162 (41) West1035 (23)1105 (21)605 (21) Unknown8 (0.2)8 (0.1)5 (0.2)Health insurance plan, *n* (%)\< 0.001/0.531\*\< 0.001/1.154\* Commercial4217 (95)4138 (77)1444 (50) Medicare228 (5)1233 (23)1427 (50) Modified DCI^a^, mean (SD)0.01 (0.2)0.03 (0.3)\< 0.001/0.102\*0.32 (1)\< 0.001/0.410\*Top 5 comorbidities^b^, *n* (%) Urinary tract infection178 (4)338 (6)\< 0.001/0.104\*350 (12)\< 0.001/0.303\* Depressive disorder172 (4)321 (6)\< 0.001/0.097349 (12)\< 0.001/0.309\* Acute upper respiratory infection684 (15)692 (13)\< 0.001/0.072414 (14)0.258/0.027 Hypothyroidism928 (21)1710 (32)\< 0.001/0.251\*1129 (39)\< 0.001/0.410\* Acute sinusitis225 (5)311 (6)0.114/0.032173 (6)0.076/0.042*CVD* cardiovascular disease, *CVRF* cardiovascular risk factors, *DCI* Deyo--Charlson Comorbidity Index, *ICD*, International Classification of Diseases, *SD* standard deviation, *SMD* standardized mean difference\*Significant difference *P* ≤ 0.001 and SMD ≥  0.1^a^The DCI was modified to exclude CVRF or CVD or diabetes-related conditions and calculated for each patient included in the study^b^Based on frequency of ICD medical claims (inpatient or outpatient) identified in the no-CVD/CVRF cohort

Fewer patients in the no-CVD/CVRF vs. the CVRF and the CVD cohorts were covered by Medicare plan (5% vs. 23% and 50%, respectively; *P* \< 0.001 and SMD \> 0.1 for the CVRF and CVD cohorts vs. the no-CVD/CVRF cohort). The most frequent comorbidity in all three cohorts was hypothyroidism (21% vs. 32% and 39%, respectively, for the no-CVD/CVRF, CVRF, and CVD cohorts; *P* \< 0.001 and SMD \> 0.1 for both CVRF and CVD vs. no CVD/CVRF), followed by urinary tract infection (4% vs. 6% and 12%, respectively, for the no-CVD/CVRF, CVRF, and CVD cohorts; *P* \< 0.001 and SMD \> 0.1 for CVRF vs. no CVD/CVRF) (see Table [1](#Tab1){ref-type="table"}).

Prevalence of CVD and CVRF {#Sec8}
--------------------------

The period prevalence of CVD (combined baseline and follow-up periods) was 27% (3475/12,687), which included patients who developed the condition(s) during the follow-up period. The proportions of different types of CVD for patients in this cohort were: cerebrovascular disease, 13%; heart failure, 27%; peripheral vascular disease, 43%; prior myocardial infarction, coronary artery disease (CAD), and angina, 46%; and cardiac arrhythmia, 50%. The period prevalence of CVRF was 44% (5603/12,687), and the CVRF reported were CKD (13%), obesity (22%), hypertension and ≥ 1 prescription for an antihypertensive agent (67%), and hypercholesterolemia or hyperlipidemia and ≥ 1 prescription for a lipid-modifying drug (74%).

Healthcare Resource Utilization {#Sec9}
-------------------------------

The presence of CVD/CVRF and CVD significantly increased all-cause and diabetes-related resource utilization per patient per year (see Table [2](#Tab2){ref-type="table"}). The proportion of patients with all-cause and diabetes-related inpatient admission was significantly lower in the no-CVD/CVRF vs. the CVD cohort (all-cause: 8% vs. 27%; *P* \< 0.001 and SMD \> 0.1), and the length of hospitalization was also shorter for the no-CVD/CVRF vs. the CVD cohort (all-cause: 0.5 vs. 4.9 days; *P* \< 0.001 and SMD \> 0.1). Fewer patients in the no-CVD/CVRF cohort had all-cause and diabetes-related ED visits vs. the CVRF and CVD cohorts (all-cause: 10% vs. 14% and 26%, respectively; *P* \< 0.001 and SMD \> 0.1). Likewise, the mean number of outpatient physician visits was lower for patients in the no-CVD/CVRF vs. the CVRF and CVD cohorts. Patients with CVD or with CVRF had significantly more all-cause prescription claims compared with patients with no CVD/CVRF (64.7, 42.3 vs. 25.9, respectively; all *P* \< 0.001 and SMD \> 0.1) (see Table [2](#Tab2){ref-type="table"}).Table 2Per patient per year healthcare resource utilization by diagnosis category (unadjusted analysis)No-CVD/CVRF cohort (*n* = 4445)CVRF cohort (*n* = 5371)*P* value/SMD (CVRF vs. No-CVD/CVRF cohort)CVD cohort (*n* = 2871)*P* value/SMD (CVD vs. No-CVD/CVRF cohort)All-cause Inpatient admissions, *n* (%)350 (8)577 (11)\< 0.001/0.087760 (27)\< 0.001/0.398\* Length of stay in days, mean (SD)0.5 (5.0)1.3 (8.1)\< 0.001/0.114\*4.9 (16.6)\< 0.001/0.352\* ED visits, *n* (%)447 (10)772 (14)\< 0.001/0.107\*756 (26)\< 0.001/0.333\* Outpatient physician visits, mean (SD)^a^3.5 (3.6)5.0 (5.1)\< 0.001/0.330\*8.1 (7.6)\< 0.001/0.760\* Prescription claims, mean (SD)^b^25.9 (19.3)42.3 (29.3)\< 0.001/0.663\*64.7 (45.6)\< 0.001/1.112\*Diabetes-related Inpatient admissions, *n* (%)338 (8)560 (10)\< 0.001/0.095739 (26)\< 0.001/0.415\* Length of stay in days, mean (SD)0.5 (4.8)1.3 (7.8)\< 0.001/0.115\*4.7 (16.3)\< 0.001/0.347\* ED visits, *n* (%)156 (4)379 (7)\< 0.001/0.113\*525 (18)\< 0.001/0.301\* Outpatient physician visits, mean (SD)^a^1.8 (2.0)2.5 (2.7)\< 0.001/0.282\*3.6 (3.8)\< 0.001/0.585\* Prescription claims, mean (SD)^b^8.0 (5.2)8.4 (6.2)\< 0.001/0.0728.8 (7.8)\< 0.001/0.121\**CVD* cardiovascular disease, *CVRF* cardiovascular risk factors, *ED* emergency department, *SD* standard deviation, *SMD* standardized mean difference\*Significant difference *P* \< 0.05 and SMD ≥ 0.1^a^For all-cause, *n* (%): 3672 (83%), 4621 (86%), and 2493 (87%) patients in the no-CVD/CVRF, CVRF, and CVD cohorts, respectively; for diabetes-related, *n* (%): 2994 (67%), 3981 (74%), and 2215 (77%) patients in the no-CVD/CVRF, CVRF, and CVD cohorts, respectively^b^For all-cause, *n* (%): 4445 (100%), 5371 (100%), and 2871 (100%) patients in the no-CVD/CVRF, CVRF, and CVD cohorts, respectively; for diabetes-related, *n* (%): 4393 (99%), 5278 (98%), and 2803 (98%) patients in the no-CVD/CVRF, CVRF, and CVD cohorts, respectively

Healthcare costs per patient per year for the different cohorts are shown in Fig. [2](#Fig2){ref-type="fig"}. The all-cause and diabetes-related costs associated with inpatient admission were lower for patients with no CVD/CVRF vs. CVRF and CVD (*P* \< 0.001 and SMD \> 0.1 for both cohorts vs. the no-CVD/CVRF cohort). All-cause pharmacy costs were significantly higher for patients with CVRF and CVD compared with those with no CVD/CVRF, but diabetes-related pharmacy costs were only significantly higher for the CVRF cohort vs. the no-CVD/CVRF cohort. The same trend was observed for total costs, which included medical (outpatient, inpatient, and ED costs) and prescription costs (all-cause: \$30,241 for the CVD and \$16,220 for the CVRF cohorts vs. \$11,761 for the no-CVD/CVRF cohort; *P* \< 0.05 and SMD ≥ 0.1 for both; diabetes-related: \$17,756 for the CVD and \$9453 for the CVRF cohorts vs. \$7113 for the no-CVD/CVRF cohort; *P* \< 0.05 and SMD ≥ 0.1 for both).Fig. 2Per patient per year healthcare costs at 12 months of follow-up (unadjusted analysis). Note: ED costs are not shown in the chart because the values are much smaller relative to those for the other categories (all-cause: \$35, \$73, and \$178 for the no-CVD/CVRF, CVRF, and CVD cohorts, respectively; diabetes-related: \$11, \$28, and \$70 for the no-CVD/CVRF, CVRF, and CVD cohorts, respectively). However, the total costs shown on top of the bars include ED costs. Outpatient costs include costs for outpatient visits and service costs, whereas inpatient costs include only costs for inpatient admissions. Numbers of patients in the different cohorts were as follows: 4445 in the no-CVD/CVRF cohort, 5371 in the CVRF cohort, and 2871 in the CVD cohort. \*Significant difference: *P* \< 0.05 and SMD ≥ 0.1 (vs. no CVD/CVRF). *CVD* cardiovascular disease, *CVRF* cardiovascular risk factors, *ED* emergency department, *SMD* standardized mean difference

Multivariate Models Adjusting for Confounders {#Sec10}
---------------------------------------------

When adjusted for confounding factors, the results for healthcare resource utilization were consistent with those obtained in the unadjusted analysis (see the ESM). The CVD and CVRF cohorts had significantly higher healthcare costs compared with the no-CVD/CVRF cohort after controlling for confounders (all *P* \< 0.001) (see Table [3](#Tab3){ref-type="table"}). The estimated differences in overall all-cause and diabetes-related costs were smaller between the CVRF and the no-CVD/CVRF cohorts than between the CVD and the no-CVD/CVRF cohorts. Similar results were noted for all-cause and diabetes-related medical costs, with a larger estimated difference in medical costs for CVD vs. no CVD/CVRF compared to CVRF vs. no CVD/CVRF.Table 3Differences in mean predicted healthcare costs at 12 months of follow-up (adjusted analysis)CVRF cohortNo-CVD/CVRF cohortCost difference^a^95% CI*P* valueCVD cohortNo-CVD/CVRF cohortCost difference^a^95% CI*P* valueAll-cause Overall^b^\$16,423\$11,982\$4441\$4027, \$4855\< 0.001\*\$29,847\$11,991\$17,856\$16,725, \$18,987\< 0.001\* Medical\$5907\$3376\$2530\$2288, \$2773\< 0.001\*\$17,720\$3372\$14,348\$13,337, \$15,358\< 0.001\* Pharmacy\$10,532\$8586\$1946\$1625, \$2267\< 0.001\*\$12,163\$8595\$3568\$3144, \$3991\< 0.001\*Diabetes-related Overall^b^\$9527\$7232\$2295\$2117, \$2473\< 0.001\*\$17,282\$7237\$10,045\$9543, \$10,546\< 0.001\* Medical\$4126\$2253\$1874\$1695, \$2053\< 0.001\*\$12,269\$2243\$10,027\$9505, \$10,548\< 0.001\* Pharmacy^c^\$5409\$4969\$440\$349, \$532\< 0.001\*------*CI* confidence interval, *CVD* cardiovascular disease, *CVRF* cardiovascular risk factors\*Significant difference *P* \< 0.05^a^vs. no-CVD/CVRF cohort^b^Pharmacy and medical costs^c^Diabetes-related pharmacy cost difference between CVD vs. no-CVD/CVRF cohort is not significant in the unadjusted analysis, so it is not part of the multivariate analysis

Discussion {#Sec11}
==========

This analysis of real-world data on the disease prevalence and economic outcomes associated with CVRF and CVD in T1D from a large US managed care program database showed that more than one in five adults with T1D have CVD, and that more than two in five have CVRF. These patients with CVD or CVRF have higher healthcare expenditures vs. those without these comorbidities.

As expected, patients in the no-CVD/CVRF cohort were younger than those in the CVRF and CVD cohorts, with fewer patients enrolled in Medicare. The most prevalent (period prevalence) CVD comorbidity was cardiac arrhythmia, with approximately half of the patients with CVD-associated comorbidities having a diagnosis code for this condition, followed by CAD/myocardial infarction/angina. Hypercholesterolemia, hyperlipidemia, and hypertension were the most frequent CVRF identified, followed by obesity in more than one-fifth of patients.

In the initial analysis of the T1D Exchange clinic registry in the US, which included only approximately 11% (2861/25,833) of patients aged ≥ 50 years, almost one-fourth were overweight or obese at the time of diagnosis. The frequency of kidney disease, including micro- and macroalbuminuria, kidney failure, glomerular filtration rate \< 60 mL/min, and need for dialysis or kidney transplant, in patients aged ≥ 50 years was 29% \[[@CR17]\]. A subsequent data update indicated a similar percentage of obese patients specifically in this age group (29%) \[[@CR18]\], and a subanalysis of 9481 adult patients conducted in 2016--2017 revealed that 27% of women and 29% of men aged ≥ 50 years were obese \[[@CR19]\]. These rates are similar to the overall prevalence of 22% observed in our analysis. Shah et al. \[[@CR18]\] also identified 20% and 23% of women and men, respectively, with hypertension and 45% and 56% with dyslipidemia in this age group \[[@CR19]\], which are lower rates than the ones for the CVRF cohort in our analysis (67% for hypertension and 74% for dyslipidemia).

A cross-sectional study of slightly older patients with T1D (≥ 60 years) compared outcomes obtained from the analyses of the T1D Exchange registry (*n* = 1283) in the US and the German/Austrian diabetes patient registries (*n* = 2014) and showed very similar rates of obesity (25%). History of myocardial infarction and stroke was reported less frequently in the T1D Exchange registry than in its European counterparts \[myocardial infarction: 6% vs. 9%, 99% confidence interval (CI) of difference 1--5%, respectively; stroke: 2% vs. 8%; 99% CI 3--7%\], although no differences in body mass index were observed \[[@CR20]\]. Our analysis revealed a higher prevalence for CVD; although our definition for CVD was much broader (including heart failure, cardiac arrhythmia, and peripheral artery disease, and not just limited to prior stroke and myocardial infarction), it must also be taken into consideration that the cohorts we analyzed were part of a broader population of T1D patients than the one in the T1D Exchange registry, which was restricted to the main diabetes care centers in the US. Therefore, there may be potential differences between these cohorts in the care provided.

The results of the unadjusted analysis showed that presence of CVD and/or CVRF had a negative impact on all-cause and diabetes-related healthcare resource utilization. The magnitude of the differences vs. the no-CVD/CVRF cohort was in fact larger for the CVD than for the CVRF cohort. When adjusted for confounding factors, the results for healthcare resource utilization were consistent with those obtained in the unadjusted analysis, and the cost data reflected the differences seen in healthcare resource utilization. All-cause and diabetes-related overall costs for the CVD cohort were almost double those for the CVRF cohort. Therefore, the estimated difference in overall and medical costs vs. the no-CVD/CVRF cohort was significantly higher for the CVD cohort than for the CVRF cohort.

The present results are not entirely surprising considering previous reports in the literature. Data from the Medical Expenditure Panel Survey, which was conducted in the US in 2012 and involved 25,317 participants, showed that the rate of healthcare resource utilization for individuals with diabetes at a lower risk of developing CVD (i.e., patients with ≤ 1 CVRF, comprising 54% of the study population) was less than that for those at higher risk (i.e., patients with ≥ 2 CVRF, which represented 46% of the overall study population, including 7% with ≥ 4 CVRF), defined as presence of hypertension and/or lack of physical exercise, smoking, and obesity \[[@CR21]\]. The likelihood of needing to purchase/refill a prescription and having an outpatient visit was reduced by approximately 50% among patients with a favorable risk profile. This reduced use of resources translated to lower associated healthcare costs (i.e., prescription medications, hospitalizations, outpatient visits, and other expenses such as care at home and medical supplies) for patients with diabetes and an optimal CVRF profile compared to those with diabetes and a poor CVRF profile (\$6461 vs. \$9006; *P* \< 0.001) \[[@CR21]\]. This difference of \$2545 was lower than the adjusted difference for all-cause healthcare costs between the CVRF cohort and the no-CVD/CVRF cohort (\$4441, 95% CI \$4027--4855; *P* \< 0.001) in the present analysis, which is not unexpected given that the optimal category group in the study by Feldman et al. \[[@CR21]\] could have the presence of one risk factor.

UnitedHealthcare is the largest provider of health insurance in the US. Therefore, the Optum^®^ Clinformatics™ Data Mart represents patients from all regions of the country, and the large size and regional diversity of the data should help mitigate some forms of selection bias. However, it is possible that patients insured at UnitedHealthcare may differ in demographic and healthcare-seeking behaviors from those insured by other providers or the uninsured (who represented approximately 9% of the population in 2016) \[[@CR22]\]. This analysis was not able to assess this type of selection bias given the lack of access to data from other insurance companies or the uninsured, and there is also the possibility of selection bias due to the requirement for the patients to be continuously enrolled in the health plan for 2 years. The generalizability of the population evaluated to the broader adult population of patients with T1D may be also limited, since this database overrepresents commercially insured and Medicare-covered patients. Finally, diagnosis coding errors ultimately affect the analysis and, without a medical chart validation, it is possible that a small proportion of the patients included in the analysis may have been misclassified as having T1D. Limitations on capturing CKD and obesity as a risk factor using ICD codes may not be as comprehensive as using laboratory data, so some cases of CKD/obesity may not have been captured.

Conclusion {#Sec12}
==========

In summary, more than one in five adults with T1D have CVD, and approximately two in five have CVRF, with higher healthcare expenditures seen for these patients compared to those without CVD or CVRF. The management of T1D is complex and costly, and the tendency of T1D to have an earlier onset than T2D results in longer exposure to the complications of the disease in this patient population. Potentially, better management of CVD and/or related risk factors in T1D could significantly reduce the economic burden and improve outcomes for these patients.
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